Cargando…

“Budget Impact Analyses”: A Practical Policy Making Tool for Drug Reimbursement Decisions

In the present article, Budget Impact Analysis as an effective, practical financial tool has been introduced to the policy makers for improving drug formulary and reimbursement decision making. In Iran, Ministry of Health (MOH), health insurance organizations, and health care providers such as hospi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jamshidi, Hamid Reza, Foroutan, Naghmeh, Salamzadeh, Jamshid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Shaheed Beheshti University of Medical Sciences 2014
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177634/ https://www.ncbi.nlm.nih.gov/pubmed/25276214

Ejemplares similares

Budget impact analysis of conversion from cyclosporine to sirolimus as immunosuppressive medication in renal transplantation therapy
por: Foroutan, Naghmeh, et al.
Publicado: (2013)

Costs of Treatment after Renal Transplantation: Is it Worth to Pay More?
por: Salamzadeh, Jamshid, et al.
Publicado: (2014)

Budget impact analysis of the new reimbursement policy for day surgery in Thailand
por: Suphanchaimat, Rapeepong, et al.
Publicado: (2019)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Drug pricing and reimbursement information management: processes and decision making in the global economy
por: Tsourougiannis, Dimitrios
Publicado: (2017)

A Process for Evaluating Quality Decision-Making Practices During the Development, Review and Reimbursement of Medicines
por: Bujar, Magdalena, et al.
Publicado: (2020)

A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions
por: Foroutan, Naghmeh, et al.
Publicado: (2018)

Budget Impact of Publicly Reimbursed Prescription Medicines in the Republic of Srpska
por: Petrusic, Tamara, et al.
Publicado: (2015)

Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion
por: Detiček, Andreja, et al.
Publicado: (2018)

Reimbursement decision-making system in Poland systematically compared to other countries
por: Mela, Aneta, et al.
Publicado: (2023)

Decision-making under uncertainty in environmental health policy: new approaches
por: Reis, Jacques, et al.
Publicado: (2019)

Organizational performance, Marketing strategy, and Financial strategic alignment: an empirical study on Iranian pharmaceutical firms
por: Mohammadzadeh, Mehdi, et al.
Publicado: (2013)

How Should the Value Attributes of Novel Antibiotics Be Considered in Reimbursement Decision Making?
por: Morton, Alec, et al.
Publicado: (2019)

Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies
por: Jakovljevic, Mihajlo, et al.
Publicado: (2017)

Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey
por: Polisena, Julie, et al.
Publicado: (2017)

Role of centralized review processes for making reimbursement decisions on new health technologies in Europe
por: Stafinski, Tania, et al.
Publicado: (2011)

The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?
por: Lux, Michael Patrick, et al.
Publicado: (2021)

Budget Impact of Introducing Linagliptin into Bosnia and Herzegovina Health Insurance Drug Reimbursement List in 2016-2018
por: Catic, Tarik, et al.
Publicado: (2017)

Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement
por: Tse, Vicki C, et al.
Publicado: (2011)

Informed decision‐making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments
por: Weir, Christopher J., et al.
Publicado: (2022)

Future Research and Policy Directions in Physician Reimbursement
por: McMenamin, Peter
Publicado: (1981)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
por: Gray, Andrew L
Publicado: (2015)

Challenges and opportunities for pharmaceutical pricing and reimbursement policies
por: Vogler, Sabine, et al.
Publicado: (2015)

Using multicriteria decision analysis during drug development to predict reimbursement decisions
por: Williams, Paul, et al.
Publicado: (2014)

HIA as a standard tool for effective decision-making on NCD policies
por: Pekarcikova, J
Publicado: (2023)

Editorial: Role of health economic data in policy making and reimbursement of new medical technologies, Volume II
por: Jakovljevic, Mihajlo, et al.
Publicado: (2023)

Use of health technology assessment in drug reimbursement decisions in China
por: Chen, Wen, et al.
Publicado: (2023)

Use of health technology assessment in drug reimbursement decisions in China
Publicado: (2023)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
por: Elvira, David, et al.
Publicado: (2023)

The design and development of an encounter tool to support shared decision making about preventing cardiovascular events
por: Hartasanchez, Sandra A., et al.
Publicado: (2022)

Pharmacoeconomic Analysis of Antiepileptic Reimbursement for Neuropathic Pain in Bosnia and Herzegovina – Budget Impact Analysis of Pregabalin
por: Catic, Tarik, et al.
Publicado: (2018)

Pre-reimbursement: early assessment for coverage decisions
por: Grössmann, Nicole, et al.
Publicado: (2019)

Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs
por: Docteur, Elizabeth, et al.
Publicado: (2015)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
por: Paulden, Mike, et al.
Publicado: (2014)

A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers
por: Foroutan, Naghmeh, et al.
Publicado: (2019)

Medicaid nursing home reimbursement policies, rates, and expenditures
por: Harrington, Charlene, et al.
Publicado: (1984)

Hospitalizations of nursing homes residents: the role of reimbursement policies
por: Ashton, Toni
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bp7aojbievasnjga2bk3atte61